The Association Between EGFR Mutations and Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of a Therapeutic Paradigm Shift

Abstract

Introduction: Advanced Non-Small Cell Lung Cancer (NSCLC) carries a poor prognosis, with conventional chemotherapy offering limited benefit. The development of therapies targeting the Epidermal Growth Factor Receptor (EGFR) pathway, such as EGFR tyrosine kinase inhibitors (TKIs), resulted in remarkable tumor responses, but only in a select minority of patients.

Literature Review: A review of pivotal scientific literature reveals that this differential sensitivity was explained by a landmark molecular discovery. Seminal studies identified that the tumors of patients who experienced dramatic responses to EGFR TKIs harbored specific, somatic, activating mutations within the EGFR gene itself. This discovery provided a powerful genetic basis for TKI sensitivity. This hypothesis was subsequently validated in large, prospective, randomized clinical trials. The I-PASS study, for example, definitively showed that patients with EGFR-mutant tumors had significantly superior progression-free survival when treated with a TKI compared to standard chemotherapy, whereas the opposite was true for patients with EGFR wild-type tumors.

Conclusion: This body of evidence forged a critical and actionable link between a specific molecular biomarker and a targeted therapy. It transformed the treatment of advanced NSCLC from a non-specific, histology-based approach to a personalized, biomarker-driven strategy, establishing a new standard of care and a foundational paradigm for modern precision oncology.